Pelvic Inflammatory Disease Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Pelvic Inflammatory Disease Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The pelvic inflammatory disease therapeutics market studied was anticipated to witness a CAGR of nearly 5.6% during the forecast period.

The studied market was impacted by the pandemic. Various research studies provide insight into the impact of the pandemic on the market. According to the article titled, ‘Sexually transmitted infections during the COVID-19 outbreak: comparison of patients referring to the service of sexually transmitted diseases during the sanitary emergency with those referring during the common practice’ was published by researchers based in Italy in June 2020. It stated that prior to the national lockdown in Italy, a total of 1,081 medical provisions were delivered by the STDs Service of Dermatology, Bologna. The percentage of visits for prophylaxis declined after the lockdown, while visits for syphilis, gonococcal pharyngitis, and inflammatory genital diseases increased significantly. As per the article titled, ‘Measuring the Impact of the COVID-19 Pandemic on Sexually Transmitted Diseases Public Health Surveillance and Program Operations in the State of California’, published in August 2020, a comparative study for January–June 2020 to January–June of 2019 data found that there were decreases in reported cases of chlamydia (31%), late syphilis (19%), primary/secondary syphilis (15%), early nonprimary non-secondary syphilis (14%), and gonorrhea (13%) during the COVID-19 pandemic. Thus, the market was adversely impacted by the pandemic.

The major factors attributing to the growth of the market are rise in urinary tract infections, sexually transmitted diseases (STDs), and severe complications associated with PID, such as increased rate of Polycystic ovary syndrome (PCOS) cases, and infertility. According to the article by Ayan Sabih and Stephen W. Leslie published by the National Institute of Health in February 2021, complicated UTI incidence is highly associated with specific risk factors. For instance, there is a 10% estimated daily risk of developing bacteriuria with indwelling bladder catheters, and there is up to 25% risk that bacteriuria will progress to a urinary track infection. In June 2022, the Centers for Disease Control and Prevention recommended and issued guidelines for screening of sexually transmitted diseases in order to create awareness towards screening programs for STDs and the increasing burden of STDs across the globe. It has issued separate STD screening guidelines for every group of the population such as women, pregnant women, men who have sex with women, men who have sex with men, transgender and gender diverse persons, and persons with HIV. However, in March 2022, the Department of Health of the State of New Jersey organized the Sexually Transmitted Disease (STD) Program with an aim to reduce and prevent the effects of the sexually transmitted disease in New Jersey through partner services, education, technical assistance, surveillance, and partnerships with local health and community organizations. Therefore, such programs are anticipated to positively impact the market over the forecast period.

However, the stringent regulatory framework that delays the approval of products and expensive patented products and severe complications associated with the medication is expected to hinder the market growth.

Key Market TrendsThe Tetracyclines Segment is Expected to Hold the Major Market Share in the Pelvic Inflammatory Disease Therapeutics Market

Tetracycline drugs are expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment and recommendations of cephalosporin along with doxycycline, a tetracycline drug by the Centers for Disease Control and Prevention (CDC) as the first-line treatment of pelvic inflammatory disease. Rapid advancements in new product development with reduced side effects, coupled with the availability of a wide range of marketed products, are expected to fuel the market. The report published by the World Health Organization in November 2021, reported that more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. It also reported that every year there are an estimated 374.0 million new infections with 1 out of 4 sexually transmitted infections: gonorrhea, chlamydia, trichomoniasis, and syphilis. Tetracyclines (tetracycline, doxycycline, minocycline, and tigecycline) are a class of drugs used to manage and cure numerous bacterial infections, according to a research report released in July 2022 under the title "Tetracycline." Tetracyclines are categorized as broad-spectrum antibiotics that suppress protein synthesis. Tetracyclines are an effective treatment for bacterial infections, and this activity discusses their indications, mode of action, and contraindications. This exercise will emphasize the mechanism of action, adverse event profile, and pertinent interactions important for healthcare team members involved in treating these illnesses, and infected patients. Thus, such advantages provided in research studies are expected to increase the adoption of drugs which is expected to increase the market growth.

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the studied market throughout the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, polycystic ovary syndrome, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, etc., due to changes in lifestyles and a rise in stress among women in the United States, which registers the highest revenue in the region. For instance, in April 2022, a report published by the Centers for Disease Control and Prevention (CDC) titled "Sexually Transmitted Disease Surveillance, 2020" stated that STDs remain a significant public health concern in the country. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020 with a total of 1,579,885 cases reported to the CDC. The CDC received reports of 677,769 different gonorrhea infections in 2020. 2020 saw 133,945 cases of syphilis throughout all phases, including 41,655 cases of the disease's primary and secondary (P&S) stages, which are the most contagious. By raising the demand for such diseases' therapeutic processes, the country's market growth is thus anticipated to expand with the prevalence of STDs. Similarly, in February 2022, a report published titled "Report on sexually transmitted infection surveillance in Canada, 2019" stated that Chlamydia rates have increased by 33.1% over the past decade. In 2019, a total of 139,386 cases of chlamydia were reported, for a rate of 370.8 cases per 100,000 population. Gonorrhea rates have almost tripled (181.7% increase) over the past decade. Thus, the increasing prevalence of STIs is expected to increase the demand for therapeutics and will increase the market growth.

Competitive Landscape

The pelvic inflammatory disease therapeutics market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the world. Furthermore, a steep rise in the availability of public funding for the development of these drugs is also expected to fuel the market. Some of the companies which are currently dominating the market are Bristol‑Myers Squibb Company, Pfizer Inc., Mayne Pharma, Perrigo Company PLC, and Viatris among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.